Boston Scientific was successful in receiving FDA and CE approval for its EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) System. The S-ICD is implanted in patients who are prone to sudden cardiac arrests caused by heart rhythm disorder. In a standard S-ICD system, the leads of the defibrillator do not touch the heart. This reduces the risks associated with conventional transvenous implantable cardioverter-defibrillators (T-ICDs) including blood infection and lead replacement. The EMBLEM S-ICD will be launched in a limited market in certain European health institutions, which will be followed by a wider release of the product in May 2015. This product plans to hit the U.S. markets in the third quarter of 2015.
Help employers find you! Check out all the jobs and post your resume.
